CRVS NASDAQ
Corvus Pharmaceuticals, Inc.
1W: -6.2%
1M: -23.2%
3M: -28.1%
YTD: +48.9%
1Y: +50.1%
3Y: +651.7%
5Y: +60.3%
$10.90
-0.03 (-0.27%)
Weekly Expected Move ±7.8%
$9
$10
$11
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2021-11-02
Earliest Filing
2026-03-13
Latest Filing
partner: 7
Counterparties (Filed by CRVS)
7 relationshipsCompanies named in CRVS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Sales agent for the amended open market sale agreement | 2026-03-13 | View |
| NewLimit, Inc. | — | partner | Entered into a sub-sublease agreement to lease office space. | 2024-10-23 | View |
| Theravance Biopharma US, Inc. | TBPH | partner | Identified as the Prime Sublandlord in the underlying sublease agreement. | 2024-10-23 | View |
| Theravance, Inc. | TBPH | partner | Identified as the predecessor-in-interest to the Prime Sublandlord. | 2024-10-23 | View |
| HMS Gateway Office L.P. | — | partner | Identified as the predecessor-in-interest to the Master Landlord. | 2024-10-23 | View |
| ARE-901/951 Gateway Boulevard, LLC | — | partner | Identified as the successor to the Master Landlord. | 2024-10-23 | View |
| Jefferies LLC | JEF | partner | Acted as sales agent for an open market sales agreement to sell up to $40,000,000 of common stock. | 2021-11-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-22 | Officer/Director Change | View | |
| 2026-06-12 | Shareholder Vote | View | |
| 2026-05-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-23 | Officer/Director Change | View | |
| 2026-03-13 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-23 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-20 | Other Events | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-04-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-12-18 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR